# US 2015/0031677 A1 · Trioxane thioacetal monomers and dimers and methods of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0031677 A1
- Document ID: US20150031677A1
- Status: Published application
- Kind: A1
- Application number: 14/381,494
- Filed: 2013-02-28
- Published: 2015-01-29
- Earliest claimed: 2012-02-28
- Assignees: The Johns Hopkins University
- Applicants: The Johns Hopkins University
- Inventors: Gary H. Posner; Alexander M. Jacobine; Rachel D. Slack; Jennifer R. Mazzone
- Web page: https://patentgrep.com/patent/US20150031677A1

## CPC

- C07D 493/22: in which the condensed system contains four or more hetero rings
- A61K 31/357: having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K 31/4192: 1,2,3-Triazoles
- A61K 31/4709: Non-condensed quinolines and containing further heterocyclic rings
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- C07D 493/18: Bridged systems
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Monomeric and dimeric trioxane thioacetals and methods of their use for treating subjects infected with malaria or other parasitic infectious diseases including, but not limited to, toxoplasmic infection; subjects afflicted with psychiatric conditions associated with toxoplasmic infection; and subjects afflicted with cancer.

## Claims

### Claim 1

A compound of Formula (I):
wherein:
R1 is —(CH2)n—O—R2a or —(CH2)n-1—C(═O)—R2b, wherein n is an integer from 2 to 11; and
R2a is selected from the group consisting of H; —CH2C≡CH; —CH2—C(═CH2)R3, wherein R3 is halogen; —CH2—R4, wherein R4 is selected from the group consisting of:
wherein R3 is as defined above; and —(C═X1)—R5; wherein X1 is O or S; and R5 is selected from the group consisting of substituted or unsubstituted alkyl, alkoxyl, substituted or unsubstituted aryl, —SR6, —NR6R7; wherein R6 and R7 are each selected from the group consisting of H, substituted or unsubstituted alkyl; and
R2b is selected from the group consisting of hydroxyl; substituted or unsubstituted alkoxyl; substituted or unsubstituted aryloxyl; and —NR6R7, wherein R6 and R7 are as defined above; under the proviso that if R2b is hydroxyl, n cannot be 3;
or an enantiomer, diastereomer, racemate or pharmaceutically acceptable salt, prodrug, or solvate thereof.

### Claim 2 (depends on 1)

The compound of claim 1, wherein R1 is —(CH2)n—O—R2a and R2a is selected from the group consisting of H; OH, —CH2C≡CH; —CH2—C(═CH2)Cl; —(C═O)—CH3; —(C═O)—C(CH3)3; —(C═O)—N(CH2CH3)2; —(C═O)—N(CH(CH3)2)2; —(C═O)—S—CH3; —(C═O)—S—CH2CH3CH3; —(C═O)—S—C(CH3)3; —(C═S)—S—CH3; —(C═O)-(halogenated phenyl); —(C═O)—OR8, wherein R8 is selected from the group consisting of substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, and substituted or unsubstituted aryl;

### Claim 3 (depends on 2)

The compound of claim 2, wherein the compound of Formula (I) is selected from the group consisting of:

### Claim 4 (depends on 1)

The compound of claim 1, wherein R1 is —(CH2)n-1—C(═O)—R2b and R2b is selected from the group consisting of hydroxyl; methoxyl; t-butoxyl; 3-fluorophenoxyl; and —NR6R7, wherein R6 is H and R7 is selected from the group consisting of 4-fluorophenyl and 3-(SCH3)-phenyl.

### Claim 5 (depends on 4)

The compound of claim 4, wherein the compound of Formula (I) is selected from the group consisting of:
under the proviso that if R2b is hydroxyl, n cannot be 3.

### Claim 6

A compound of Formula (II):
wherein:
m and n can be the same or different and are each independently an integer selected from 3 or 6; or
an enantiomer, diastereomer, racemate or pharmaceutically acceptable salt, prodrug, or solvate thereof.

### Claim 7

A compound of Formula (III):
wherein:
each n is an integer independently selected from the group consisting of 3 and 6;
L is a linking group selected from the group consisting of:
or an enantiomer, diastereomer, racemate or pharmaceutically acceptable salt, prodrug, or solvate thereof.

### Claim 8

A compound of Formula (IV):
wherein:
each n is an integer independently selected from the group consisting of 3 and 6;
L is a linking group selected from the group consisting of:
wherein:
m is an integer from 2 to 8;
R is selected from the group consisting of alkyl, cycloalkyl, heteroalkyl, aryl, and heteroaryl, each of which can be substituted or unsubstituted; or
an enantiomer, diastereomer, racemate or pharmaceutically acceptable salt, prodrug, or solvate thereof.

### Claim 9

A compound of Formula (V):
wherein:
each n is an integer independently selected from the group consisting of 3 and 6;
L is a linking group selected from the group consisting of:
wherein:
m is an integer from 2 to 8;
R is selected from the group consisting of alkyl, cycloalkyl, heteroalkyl, aryl, and heteroaryl, each of which can be substituted or unsubstituted; or
an enantiomer, diastereomer, racemate or pharmaceutically acceptable salt, prodrug, or solvate thereof.

### Claim 10 (depends on 1)

A pharmaceutical composition comprising a compound of claim 1.

### Claim 11

A method for preventing, controlling or treating an infectious disease in a subject in need of such treatment, the method comprising administering to the subject a therapeutically-effective amount of a compound of Formula (I-V) or an enantiomer, diastereomer, racemate or pharmaceutically acceptable salt, prodrug, or solvate thereof.

### Claim 12 (depends on 11)

The method of claim 11, wherein the infectious disease comprises a parasitic disease selected from the group consisting of a plasmodia parasite infection, a T. gondii infection, a trypanosome parasite infection, and a Cryptosporidium parasite infection.

### Claim 13 (depends on 11)

The method of claim 11, further comprising administering to the subject a quinoline anti-malarial drug or an antifolate concurrently or sequentially with the compound of Formula (I-V).

### Claim 14 (depends on 13)

The method of claim 13, wherein the wherein the quinoline anti-malarial drug is selected from the group consisting of chloroquine, quinine, mefloquine, and primaquine.

### Claim 15 (depends on 13)

The method of claim 13, wherein the antifolate is lumefantrine.

### Claim 16

A method for treating a psychiatric disorder associated with a toxoplasma infection in a subject in need of treatment thereof, the method comprising administering to the subject a therapeutically-effective amount of a compound of Formula (I-V) or an enantiomer, diastereomer, racemate or pharmaceutically acceptable salt, prodrug, or solvate thereof.

### Claim 17 (depends on 16)

The method of claim 16, wherein the psychiatric disorder is schizophrenia.

### Claim 18 (depends on 16)

The method of claim 16, further comprising administering to the subject one or more antipsychotic drugs selected from the group consisting of chlorpromazine, haloperidol, fluphenazine, thiothixene, trifluoperazine, perphenazine, and thioridazine, clozapine, risperidone, olanzapine, quetiapine, ziprasidone, and aripiprazole concurrently or sequentially with the compound of Formula (I-V).

### Claim 19

A method for treating cancer in a subject in need of treatment thereof, the method comprising administering to the subject a therapeutically-effective amount of a compound of Formula (I-V).

### Claim 20 (depends on 19)

The method of claim 19, wherein the cancer is selected from the group consisting of leukemia, non-small cell lung cancer, colon cancer, central nervous system cancer, melanoma cancer, ovarian cancer, renal cancer, prostate cancer, and breast cancer.
